191102-79-1

Basic information

• Product Name: GGTI 2133
• Synonyms: L-Leucine, N-[4-[(1H-imidazol-5-ylmethyl)amino]-2-(1-naphthalenyl)benzoyl]-
• CAS NO: 191102-79-1
• Molecular Formula: C27H28N4O3
• Molecular Weight: 456.53622
• Product Categories: Amino Acids & Derivatives, Chiral Reagents, Heterocycles, Inhibitors
• Mol File: 191102-79-1.mol
• Article Data: 0

Chemical Properties

• Melting Point: 103-118.5 °C
• Appearance: white/solid
• Storage Temp.: −20°C
• Solubility: DMSO: 25 mg/mL
• CAS DataBase Reference: GGTI 2133(CAS DataBase Reference)
• NIST Chemistry Reference: GGTI 2133(191102-79-1)
• EPA Substance Registry System: GGTI 2133(191102-79-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 191102-79-1(Hazardous Substances Data)

Usage

Description

GGTI 2133 is an inhibitor of protein geranylgeranyltransferase-I, a key enzyme involved in the post-translational modification of proteins. It has been shown to increase prelamin A accumulation by inhibiting the ZMPSTE24 protein in human fibroblasts. GGTI 2133 has also demonstrated its potential in inhibiting the proliferation and migration of human oral squamous cell carcinoma cells through the involvement of RhoA and RalB proteins.

Uses

Used in Pharmaceutical Industry:
GGTI 2133 is used as an inhibitor for protein geranylgeranyltransferase-I for its potential role in the treatment of various diseases related to the malfunctioning of this enzyme. By targeting this enzyme, GGTI 2133 may help in the development of novel therapeutic strategies for conditions associated with its dysregulation.
Used in Cancer Research:
GGTI 2133 is used as an inhibitor for protein geranylgeranyltransferase-I in cancer research, particularly in the context of human oral squamous cell carcinoma. Its ability to inhibit the proliferation and migration of cancer cells through the involvement of RhoA and RalB proteins makes it a promising candidate for further investigation and potential application in cancer treatment.
Used in Cellular Aging and Progeria Research:
GGTI 2133 is used as a research tool for studying the role of protein geranylgeranyltransferase-I in cellular aging and progeroid syndromes, such as Hutchinson-Gilford Progeria Syndrome. By increasing prelamin A accumulation through the inhibition of ZMPSTE24 protein, GGTI 2133 may provide insights into the molecular mechanisms underlying these conditions and contribute to the development of targeted therapies.